CY1114908T1 - Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες - Google Patents

Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες

Info

Publication number
CY1114908T1
CY1114908T1 CY20131101116T CY131101116T CY1114908T1 CY 1114908 T1 CY1114908 T1 CY 1114908T1 CY 20131101116 T CY20131101116 T CY 20131101116T CY 131101116 T CY131101116 T CY 131101116T CY 1114908 T1 CY1114908 T1 CY 1114908T1
Authority
CY
Cyprus
Prior art keywords
alkyl
hydrogen
het
alkylthio
radical
Prior art date
Application number
CY20131101116T
Other languages
English (en)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Jérôme Emile Georges Guillemont
Elisabeth Thérèse Jeanne Pasquier
David Francis Alain Lançois
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35768940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1114908(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY1114908T1 publication Critical patent/CY1114908T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Χρήση μιας ένωσης για την παρασκευή ενός φαρμάκου για τη θεραπευτική αγωγή μιας βακτηριακής μόλυνσης δεδομένου ότι η βακτηριακή μόλυνση είναι διαφορετική από μια Μυκοβακτηριακή μόλυνση, με την εν λόγω ένωση να είναι μια ένωση του Τύπου (Ιa) ή (Ιb), ένα φαρμακευτικώς αποδεκτό άλας προσθήκης οξέων ή βάσεων αυτής, μια τεταρτοταγής αμίνη αυτής, μια στερεοχημικώς ισομερής μορφή αυτής, μια ταυτομερική μορφή αυτής ή μια μορφή N-οξειδίου αυτής, όπου το R1 είναι υδρογόνο, αλο, αλοαλκυλ, κυανο, υδροξυ, Ar, Het, αλκυλ, αλκυλοξυ, αλκυλθειο, αλκυλοξυαλκυλ, αλκυλθειοαλκυλ, Αr-αλκυλ ή δι(Αr)αλκυλ· το p είναι 1, 2 ή 3· το R2 είναι υδρογόνο· αλκυλ· υδροξυ· μερκαπτο· προαιρετικά υποκατεστημένο αλκυλοξυ· αλκυλοξυαλκυλοξυ· αλκυλθειο· μονο ή δι(αλκυλ)αμινο όπου το αλκυλ μπορεί προαιρετικά να είναι υποκατεστημένο Αr· Ηet ή μία ρίζα του Τύπου (II)· το R3 είναι αλκυλ, Αr, Αr-αλκυλ, Ηet ή Ηet-αλκυλ· το q είναι μηδέν, 1, 2, 3 ή 4· το Χ είναι ένας ευθύς δεσμός ή CΗ2· τα R4 και R5 το καθένα ανεξάρτητα είναι υδρογόνο, αλκυλ ή βενζυλ· ή τα R4 και R5 μπορεί να ληφθούν μαζί, συμπεριλαμβάνοντας το Ν στο οποίο είναι προσαρτημένα· το R6 είναι υδρογόνο ή μία ρίζα του Τύπου (III)· το R7 είναι υδρογόνο, αλκυλ, Αr ή Ηet· το R8 είναι υδρογόνο ή αλκυλ· το R9 είναι οξο· ή τα R8 και R9 μαζί σχηματίζουν τη ρίζα - CH=CH-N=.
CY20131101116T 2005-08-03 2013-12-11 Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες CY1114908T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107159 2005-08-03
EP06778081.7A EP1912647B1 (en) 2005-08-03 2006-07-31 Quinoline derivatives as antibacterical agents

Publications (1)

Publication Number Publication Date
CY1114908T1 true CY1114908T1 (el) 2016-12-14

Family

ID=35768940

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131101116T CY1114908T1 (el) 2005-08-03 2013-12-11 Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες

Country Status (29)

Country Link
US (1) US8017606B2 (el)
EP (1) EP1912647B1 (el)
JP (1) JP5410753B2 (el)
KR (1) KR101337237B1 (el)
CN (1) CN101277695B (el)
AR (1) AR054889A1 (el)
AU (1) AU2006274879B2 (el)
BR (1) BRPI0614524B8 (el)
CA (1) CA2615901C (el)
CY (1) CY1114908T1 (el)
DK (1) DK1912647T3 (el)
EA (1) EA014832B1 (el)
ES (1) ES2437575T3 (el)
HK (1) HK1124233A1 (el)
HR (1) HRP20131116T1 (el)
IL (1) IL189141A (el)
JO (1) JO2952B1 (el)
MX (1) MX2008001602A (el)
MY (1) MY148241A (el)
NO (1) NO341247B1 (el)
NZ (1) NZ565283A (el)
PL (1) PL1912647T3 (el)
PT (1) PT1912647E (el)
RS (1) RS53065B (el)
SI (1) SI1912647T1 (el)
TW (1) TWI381839B (el)
UA (1) UA95916C2 (el)
WO (1) WO2007014940A2 (el)
ZA (1) ZA200801108B (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01065B (me) * 2004-01-23 2012-10-20 Janssen Pharmaceutica Nv Derivati kvinolina i njihova upotreba kao mikobakterijskih inhibitora
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
US20110059948A1 (en) * 2008-01-14 2011-03-10 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivatives as anti-mycobacterial agents
JP5246715B2 (ja) 2009-01-27 2013-07-24 独立行政法人科学技術振興機構 蛋白質架橋阻害剤およびその用途
WO2010144102A1 (en) * 2009-06-09 2010-12-16 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Material Command Pentafluorosulfanyl analogs of mefloquine
CA2869718C (en) 2012-04-27 2021-05-11 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
PL2841426T3 (pl) 2012-04-27 2017-03-31 Janssen Pharmaceutica N.V. Przeciwbakteryjne pochodne chinoliny
CN105209453B (zh) 2012-10-16 2017-06-20 詹森药业有限公司 ROR‑γ‑T的亚甲基连接的喹啉基调节剂
ES2619610T3 (es) 2012-10-16 2017-06-26 Janssen Pharmaceutica Nv Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
US9642858B2 (en) 2012-10-30 2017-05-09 University of Pittsburgh—of the Commonwealth System of Higher Education Use of resazurin, or analogs thereof, for antibacterial therapy
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
AU2013403336A1 (en) 2013-10-15 2016-04-21 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORyt
US9346782B2 (en) 2013-10-15 2016-05-24 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9624225B2 (en) 2013-10-15 2017-04-18 Janssen Pharmaceutica Nv Quinolinyl modulators of RORγt
GB201904796D0 (en) * 2019-04-04 2019-05-22 Univ Sheffield Antimicrobial agent
AR121683A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
AR121682A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317491D0 (en) 1993-08-23 1993-10-06 Fujisawa Pharmaceutical Co New compound and a process for preparation thereof
US6376670B1 (en) * 1997-06-19 2002-04-23 Sepracor Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
GB9914486D0 (en) * 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) * 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB0101577D0 (en) * 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
TW200409637A (en) * 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
ES2395237T3 (es) 2002-07-25 2013-02-11 Janssen Pharmaceutica N.V. Derivados de quinolina como compuestos intermedios para inhibidores micobacterianos
CN101817815A (zh) * 2002-10-10 2010-09-01 莫弗凯姆联合化学股份公司 具有杀菌活性的化合物
DE10316081A1 (de) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
MXPA06005686A (es) * 2003-11-20 2006-08-17 Janssen Pharmaceutica Nv 2-quinolinonas y 2-quinoxalinonas 7-fenilaquilo sustituidas como inhibidores de la poli(adp-ribosa)polimerasa.
SG151249A1 (en) * 2003-12-05 2009-04-30 Janssen Pharmaceutica Nv 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
ME01065B (me) * 2004-01-23 2012-10-20 Janssen Pharmaceutica Nv Derivati kvinolina i njihova upotreba kao mikobakterijskih inhibitora
JO2952B1 (en) 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents

Also Published As

Publication number Publication date
HRP20131116T1 (hr) 2013-12-20
MX2008001602A (es) 2008-02-19
ES2437575T3 (es) 2014-01-13
IL189141A (en) 2015-10-29
EA200800501A1 (ru) 2008-10-30
US20080255116A1 (en) 2008-10-16
CN101277695A (zh) 2008-10-01
ZA200801108B (en) 2009-05-27
NO20080955L (no) 2008-02-25
BRPI0614524B1 (pt) 2020-05-19
UA95916C2 (ru) 2011-09-26
BRPI0614524A2 (pt) 2011-04-05
NO341247B1 (no) 2017-09-25
EP1912647B1 (en) 2013-09-11
EP1912647A2 (en) 2008-04-23
JP2009503024A (ja) 2009-01-29
TWI381839B (zh) 2013-01-11
KR20080038380A (ko) 2008-05-06
JP5410753B2 (ja) 2014-02-05
SI1912647T1 (sl) 2014-01-31
US8017606B2 (en) 2011-09-13
WO2007014940A8 (en) 2007-07-05
PL1912647T3 (pl) 2014-02-28
AR054889A1 (es) 2007-07-25
IL189141A0 (en) 2008-08-07
CA2615901C (en) 2014-06-03
DK1912647T3 (da) 2013-12-02
AU2006274879B2 (en) 2013-01-10
PT1912647E (pt) 2013-12-05
RS53065B (en) 2014-04-30
TW200744594A (en) 2007-12-16
AU2006274879A1 (en) 2007-02-08
CA2615901A1 (en) 2007-02-08
WO2007014940A2 (en) 2007-02-08
WO2007014940A3 (en) 2007-03-29
HK1124233A1 (en) 2009-07-10
CN101277695B (zh) 2011-12-14
BRPI0614524B8 (pt) 2021-05-25
JO2952B1 (en) 2016-03-15
EA014832B1 (ru) 2011-02-28
MY148241A (en) 2013-03-29
KR101337237B1 (ko) 2013-12-06
NZ565283A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
CY1114908T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
CY1114318T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
CY1112247T1 (el) Παραγωγα κινολινης για τη θεραπευτικη αντιμετωπιση της λανθανουσας φυματιωσης
ECSP055611A (es) Compuestos miméticos de glucocorticoides, métodos de prepararlos, composiciones farmacéuticas
CY1113535T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
AR051989A1 (es) Derivados de quinolina como agentes antibacterianos
CY1113579T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
CY1113733T1 (el) Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων
NO20080499L (no) Kinolinderivater som antibakterielle midler
CY1112230T1 (el) Αντιβακτηριακα παραγωγα κινολινης
NO20080481L (no) Kinolinderivater som antibakterielle midler
BRPI0414778A (pt) 6-aril-7-halo-imidazo[1,2-a]pirimidinas como agentes anticáncer